Storage

What this guide covers (and what it deliberately doesn't)

This page describes what published stability research establishes about peptides in the dried and dissolved states, and what standard pharmacy practice does with that knowledge. It is a reference about a class of molecules. It is not a preparation manual, and it does not become one further down.

The distinction matters more here than anywhere else on this site, so it is worth stating flatly. Nearly everything published about peptide stability was measured on approved or investigational pharmaceutical products: formulated with stabilizing excipients, filled into a defined container-closure system, and tested under a written stability programme.^[1] None of the research-only compounds reviewed on this site has been through any part of that process. The underlying chemistry is real and it generalizes. The specification does not exist, and general chemistry is not a substitute for one.

So this page explains why peptide storage conventions look the way they do, and where those conventions stop being informative. It contains no dosing, no volume calculations, and nothing about preparing material for administration. Those questions belong with a licensed provider and a pharmacist, and this site does not sell, prescribe, or tell anyone how to obtain anything.

What the published data establishes

The dried solid is more stable than the solution, and that is the whole reason peptides are freeze-dried. Reviews of solid-state formulation are explicit that the solid state is preferred for these molecules because of their marginal stability in water, and equally explicit that the solid is not inert: chemical and physical degradation still occurs in the dried cake over the timescale of drying, distribution, and use.^[2] The broader formulation literature catalogues the routes (deamidation, oxidation, hydrolysis, disulfide scrambling, and aggregation) and treats the dried and aqueous states as genuinely different stability problems.^[1][3]

Degradation in water is specific chemistry, and it is invisible. A human growth-hormone-releasing-factor analogue held in neutral aqueous buffer at body temperature degraded principally by deamidation of one asparagine residue. The resulting peptides were estimated at roughly 400- to 500-fold and 25-fold less potent than the parent as growth hormone secretagogues, and swapping that single residue for serine extended the disappearance half-life from about 202 hours to about 1550 hours.^[4] That is a near-total loss of biological activity in a solution that would still look completely normal. Appearance is a test for gross contamination and gross precipitation. It is not a test for potency.

Light is a degradation pathway in its own right. Protein and peptide formulations are sensitive to near-ultraviolet and visible light, and the mechanistic work implicates charge-transfer chemistry in trace metal-excipient complexes as a driver of modification under ordinary visible light.^[5] "Protect from light" is not fussiness inherited from an older era of pharmacy; it names a real reaction.

Colder is not automatically safer. Aggregates of recombinant human growth hormone produced by freeze-thaw and by agitation (two stresses the authors describe as routine in manufacturing, shipping, and handling) increased immunogenicity across mouse models, and reducing aggregate size and concentration reduced it again.^[6] Freezing is a stress, not the absence of one, which is why storage conventions distinguish between refrigeration and freezing rather than treating cold as a single good.

Standard conventions and where they come from

This section is about where storage conventions come from, and it is framed that way deliberately. It is not a storage protocol, it is not a finding about any specific compound, and it does not turn into either one further down.

Storage conventions for peptide products distinguish the dry state from the solution, and refrigeration from freezing, because the chemistry in the previous section makes those genuinely different situations rather than points on a single "colder is better" scale. A lyophilized cake and its solution are two separate stability problems: the aqueous degradation routes that barely operate in the solid operate freely in water.^[1] Freezing is a stress in its own right rather than the absence of one.^[6] Light protection names a reaction, not a habit inherited from an older era of pharmacy.^[5] Where a storage statement exists on a product, that is the chemistry it is encoding.

This page does not convert any of that into temperatures, durations, or a handling routine. For the compounds reviewed here there is no product-specific stability study those numbers could be derived from, and a number invented to fill the gap would be worse than the gap. It would carry the authority of a specification while resting on nothing. What follows is the machinery that produces a real storage statement, and what its absence means.

The cold-chain convention deserves a caveat that is usually left out. A systematic review of the vaccine cold chain found accidental freezing to be pervasive across every segment of distribution: between 14% and 35% of refrigerators or transport shipments studied had exposed product to freezing temperatures, and in studies that examined all segments, between 75% and 100% of shipments had been exposed. More rigorous study designs found more freeze exposure, not less.^[7] "Keep it cold" is therefore a claim about an entire chain of custody, most of which no end reader observes, and a refrigerator at the end of that chain does not retroactively fix what happened earlier in it.

The last piece of the convention is the part with no substitute. For an approved drug product, the storage statement on the label is not a recommendation someone wrote down. Under the United States current good manufacturing practice regulations, an expiration date must be determined by stability testing, must be related to the storage conditions stated on the labelling, and the stability programme behind it must test the product in the same container-closure system in which it is marketed. Where a product is intended to be reconstituted before use, the labelling must carry expiration information for both the dry and the reconstituted forms, and the stability programme must test both. That is what makes a storage instruction mean something.

Where the guidance runs out

There is no product-specific stability data for any compound reviewed here. Every study cited above examined a different molecule in a different formulation. The direction of the effects generalizes; the numbers do not. No one should read "peptides degrade by deamidation in solution" as a shelf life for anything.

There is no expiration date, and that is a structural fact rather than a missing document. An expiration date is the output of the written stability programme described above: batches tested at statistically chosen intervals, in the marketed container, by specific validated methods. Unapproved material has never entered that process, so there is nothing for a date to be derived from. The same absence covers beyond-use dating, lot release testing, and any manufacturer storage specification. Independent analysis of pharmacy-compounded preparations, a category with substantially more regulatory oversight than unapproved research material, already documents inconsistent quality testing, exemption from good manufacturing practice requirements, and the absence of standard product labelling.^[8] The most-cited critique of that category was written by authors employed by a pharmaceutical company with a commercial interest in the comparison.^[8] Whatever bound that places on what may be assumed, unapproved research material sits further out.

Appearance answers almost nothing. The single most important consequence of the deamidation work is that a solution can lose nearly all of its biological activity with no visible change.^[4] Clarity is a screen for gross problems, not evidence of potency.

This page deliberately stops before preparation. It contains nothing about volumes, nothing about how much of anything to use, and nothing involving needles or syringes. That is not an oversight and it is not squeamishness: past the point where storage chemistry ends, every remaining question is a clinical decision, and a page cannot make a clinical decision responsibly for a reader it has never met.

Questions to bring to a provider

• Is the compound under discussion an approved product with a manufacturer's storage statement and an expiration date, or is it unapproved material where neither exists?
• If there is no stability programme behind it, what should be assumed about potency after any period of storage at all?^[1]
• Given that a degraded peptide solution can look completely normal,^[4] what would actually be checked before use, and by whom?
• What is known about how the material was transported and held before it arrived, given how often cold chains fail in both directions?^[7]
• If physical stress can generate aggregates and aggregates can be immunogenic,^[6] how does that change the risk conversation?
• A pharmacist is the right person for storage and stability questions specifically. Is one available to consult?